Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation italian pedigree.
暂无分享,去创建一个
C. Gomez-Sanchez | F. Veglio | P. Mulatero | G. Mengozzi | A. Milan | T. Williams | L. Chiandussi | S. M. di Cella
[1] C. Gomez-Sanchez,et al. Serum 18-Hydroxycortisol in Primary Aldosteronism, Hypertension, and Normotensives , 2001, Hypertension.
[2] A. Bachmann,et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. , 2000, The Journal of clinical endocrinology and metabolism.
[3] C. Gomez-Sanchez,et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. , 2000, The Journal of clinical endocrinology and metabolism.
[4] R. Lifton,et al. Glucocorticoid-remediable aldosteronism and pregnancy. , 2000, Hypertension.
[5] A. Bachmann,et al. Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I. , 1999, The Journal of clinical endocrinology and metabolism.
[6] X. Jeunemaître,et al. Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. , 1998, The Journal of clinical endocrinology and metabolism.
[7] M. Boscaro,et al. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. , 1998, The Journal of clinical endocrinology and metabolism.
[8] R. Lifton,et al. Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism. , 1997, The Journal of clinical endocrinology and metabolism.
[9] A. Bachmann,et al. Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I , 1995, Journal of hypertension.
[10] X. Jeunemaître,et al. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. , 1995, The Journal of clinical investigation.
[11] J. Connell,et al. Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression. , 1995, Clinical science.
[12] M. Stowasser,et al. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. , 1995, Biochemical and biophysical research communications.
[13] R. Lifton,et al. Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis , 1995, Steroids.
[14] T. Mune,et al. Simultaneous measurement of plasma 18-oxocortisol and 18-hydroxycortisol levels in normal man. , 1994, European journal of endocrinology.
[15] C. Gomez-Sanchez,et al. Biotin-hydrazide derivatives for the development of steroid enzyme-linked immunoassays , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[16] J. Lalouel,et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase , 1992, Nature genetics.
[17] J. Connell,et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[18] R. Lifton,et al. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. , 1992, Annals of internal medicine.
[19] J. Lalouel,et al. A chimaeric llβ-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension , 1992, Nature.
[20] M. New,et al. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism. , 1990, The Journal of clinical endocrinology and metabolism.
[21] D. Murnaghan,et al. Dexamethasone-suppressible hyperaldosteronism: a large new kindred. , 1989, Journal of human hypertension.
[22] C. Lenfant,et al. National High Blood Pressure Education Program. , 1986, Journal of the American Optometric Association.
[23] N. Glorioso,et al. Prokallikrein and kallikrein inhibitors in human urine. , 1985, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[24] C. Gomez-Sanchez,et al. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-suppressible aldosteronism. , 1984, The Journal of clinical endocrinology and metabolism.
[25] J. Gill,et al. Overproduction of sodium-retaining steroids by the zona glomerulosa is adrenocorticotropin-dependent and mediates hypertension in dexamethasone-suppressible aldosteronism. , 1981, The Journal of clinical endocrinology and metabolism.
[26] R. E. Peterson,et al. A New Form of Congenital Adrenal Hyperplasia1 , 1967 .
[27] D. Sutherland,et al. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. , 1966, Canadian Medical Association journal.
[28] G. W. Liddle,et al. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. , 1960, The Journal of clinical endocrinology and metabolism.
[29] R. Lifton,et al. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. , 1998, Hypertension.
[30] P. Corvol,et al. The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme , 1997, Nature Structural Biology.
[31] G. W. Ward. The National High Blood Pressure Education Program , 1984 .
[32] R. E. Peterson,et al. A new form of congenital adrenal hyperplasia. , 1967, The Journal of clinical endocrinology and metabolism.